Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice

Valeria Cento, Monica Tontodonati, Velia Chiara Di Maio, Maria Concetta Bellocchi, Fabrizio Valenti, Alessandra Manunta, Serena Fortuna, Daniele Armenia, Luca Carioti, Francesco Paolo Antonucci, Ada Bertoli, Francesca Trave, Pierluigi Cacciatore, Mario Angelico, Pierluigi Navarra, Avidan U. Neumann, Jacopo Vecchiet, Giustino Parruti, Sergio Babudieri, Carlo Federico PernoFrancesca Ceccherini-Silberstein

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: The used first generation protease inhibitors may be hampered by virological failure in partially interferon-sensitive patients. Aim: To investigate early hepatitis C virus (HCV)-RNA decay and quasispecies modifications, and disclose viral dynamics underlying failure. Methods: Viraemia decay at early time-points during telaprevir treatment was modelled according to Neumann et al. (1998). NS3-sequences were obtained by population-sequencing and ultradeep-454-pyrosequencing. Results: 13 treatment-experienced (8 non-responders, 5 relapsers), and two cirrhotic naïve patients, received telaprevir. +. pegylated-interferon-α. +. ribavirin.Viraemia decay was biphasic. In all patients, first-phase was rapid and consistent, with a median [interquartile-range] viraemia decay of 2.8 [2.6-3.2]. log. IU/ml within 48. h. Second-phase decay was slower, especially in failing patients: 3/3 showed 100. IU/ml at week 2. Only one patient experiencing sustained viral response showed similar kinetics.By pyrosequencing, mutational freeze was observed in all 15 patients within the first 24. h, but only in patients with sustained response afterwards. Indeed, 2/2 failing patients showed early resistance, as minor (V36A-T54A: prevalence

Original languageEnglish
Pages (from-to)233-241
Number of pages9
JournalDigestive and Liver Disease
Volume47
Issue number3
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

RNA Stability
Hepacivirus
Viremia
Therapeutics
Interferons
telaprevir
Ribavirin
Protease Inhibitors
Population

Keywords

  • Drug-resistance
  • Mathematical modelling
  • Protease inhibitors
  • Viral kinetic

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology
  • Medicine(all)

Cite this

Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice. / Cento, Valeria; Tontodonati, Monica; Di Maio, Velia Chiara; Bellocchi, Maria Concetta; Valenti, Fabrizio; Manunta, Alessandra; Fortuna, Serena; Armenia, Daniele; Carioti, Luca; Antonucci, Francesco Paolo; Bertoli, Ada; Trave, Francesca; Cacciatore, Pierluigi; Angelico, Mario; Navarra, Pierluigi; Neumann, Avidan U.; Vecchiet, Jacopo; Parruti, Giustino; Babudieri, Sergio; Perno, Carlo Federico; Ceccherini-Silberstein, Francesca.

In: Digestive and Liver Disease, Vol. 47, No. 3, 01.03.2015, p. 233-241.

Research output: Contribution to journalArticle

Cento, V, Tontodonati, M, Di Maio, VC, Bellocchi, MC, Valenti, F, Manunta, A, Fortuna, S, Armenia, D, Carioti, L, Antonucci, FP, Bertoli, A, Trave, F, Cacciatore, P, Angelico, M, Navarra, P, Neumann, AU, Vecchiet, J, Parruti, G, Babudieri, S, Perno, CF & Ceccherini-Silberstein, F 2015, 'Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice', Digestive and Liver Disease, vol. 47, no. 3, pp. 233-241. https://doi.org/10.1016/j.dld.2014.12.004
Cento, Valeria ; Tontodonati, Monica ; Di Maio, Velia Chiara ; Bellocchi, Maria Concetta ; Valenti, Fabrizio ; Manunta, Alessandra ; Fortuna, Serena ; Armenia, Daniele ; Carioti, Luca ; Antonucci, Francesco Paolo ; Bertoli, Ada ; Trave, Francesca ; Cacciatore, Pierluigi ; Angelico, Mario ; Navarra, Pierluigi ; Neumann, Avidan U. ; Vecchiet, Jacopo ; Parruti, Giustino ; Babudieri, Sergio ; Perno, Carlo Federico ; Ceccherini-Silberstein, Francesca. / Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice. In: Digestive and Liver Disease. 2015 ; Vol. 47, No. 3. pp. 233-241.
@article{43dfea2d260d4ba18b48edce426a20fc,
title = "Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice",
abstract = "Background: The used first generation protease inhibitors may be hampered by virological failure in partially interferon-sensitive patients. Aim: To investigate early hepatitis C virus (HCV)-RNA decay and quasispecies modifications, and disclose viral dynamics underlying failure. Methods: Viraemia decay at early time-points during telaprevir treatment was modelled according to Neumann et al. (1998). NS3-sequences were obtained by population-sequencing and ultradeep-454-pyrosequencing. Results: 13 treatment-experienced (8 non-responders, 5 relapsers), and two cirrhotic na{\"i}ve patients, received telaprevir. +. pegylated-interferon-α. +. ribavirin.Viraemia decay was biphasic. In all patients, first-phase was rapid and consistent, with a median [interquartile-range] viraemia decay of 2.8 [2.6-3.2]. log. IU/ml within 48. h. Second-phase decay was slower, especially in failing patients: 3/3 showed 100. IU/ml at week 2. Only one patient experiencing sustained viral response showed similar kinetics.By pyrosequencing, mutational freeze was observed in all 15 patients within the first 24. h, but only in patients with sustained response afterwards. Indeed, 2/2 failing patients showed early resistance, as minor (V36A-T54A: prevalence",
keywords = "Drug-resistance, Mathematical modelling, Protease inhibitors, Viral kinetic",
author = "Valeria Cento and Monica Tontodonati and {Di Maio}, {Velia Chiara} and Bellocchi, {Maria Concetta} and Fabrizio Valenti and Alessandra Manunta and Serena Fortuna and Daniele Armenia and Luca Carioti and Antonucci, {Francesco Paolo} and Ada Bertoli and Francesca Trave and Pierluigi Cacciatore and Mario Angelico and Pierluigi Navarra and Neumann, {Avidan U.} and Jacopo Vecchiet and Giustino Parruti and Sergio Babudieri and Perno, {Carlo Federico} and Francesca Ceccherini-Silberstein",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.dld.2014.12.004",
language = "English",
volume = "47",
pages = "233--241",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "3",

}

TY - JOUR

T1 - Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice

AU - Cento, Valeria

AU - Tontodonati, Monica

AU - Di Maio, Velia Chiara

AU - Bellocchi, Maria Concetta

AU - Valenti, Fabrizio

AU - Manunta, Alessandra

AU - Fortuna, Serena

AU - Armenia, Daniele

AU - Carioti, Luca

AU - Antonucci, Francesco Paolo

AU - Bertoli, Ada

AU - Trave, Francesca

AU - Cacciatore, Pierluigi

AU - Angelico, Mario

AU - Navarra, Pierluigi

AU - Neumann, Avidan U.

AU - Vecchiet, Jacopo

AU - Parruti, Giustino

AU - Babudieri, Sergio

AU - Perno, Carlo Federico

AU - Ceccherini-Silberstein, Francesca

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background: The used first generation protease inhibitors may be hampered by virological failure in partially interferon-sensitive patients. Aim: To investigate early hepatitis C virus (HCV)-RNA decay and quasispecies modifications, and disclose viral dynamics underlying failure. Methods: Viraemia decay at early time-points during telaprevir treatment was modelled according to Neumann et al. (1998). NS3-sequences were obtained by population-sequencing and ultradeep-454-pyrosequencing. Results: 13 treatment-experienced (8 non-responders, 5 relapsers), and two cirrhotic naïve patients, received telaprevir. +. pegylated-interferon-α. +. ribavirin.Viraemia decay was biphasic. In all patients, first-phase was rapid and consistent, with a median [interquartile-range] viraemia decay of 2.8 [2.6-3.2]. log. IU/ml within 48. h. Second-phase decay was slower, especially in failing patients: 3/3 showed 100. IU/ml at week 2. Only one patient experiencing sustained viral response showed similar kinetics.By pyrosequencing, mutational freeze was observed in all 15 patients within the first 24. h, but only in patients with sustained response afterwards. Indeed, 2/2 failing patients showed early resistance, as minor (V36A-T54A: prevalence

AB - Background: The used first generation protease inhibitors may be hampered by virological failure in partially interferon-sensitive patients. Aim: To investigate early hepatitis C virus (HCV)-RNA decay and quasispecies modifications, and disclose viral dynamics underlying failure. Methods: Viraemia decay at early time-points during telaprevir treatment was modelled according to Neumann et al. (1998). NS3-sequences were obtained by population-sequencing and ultradeep-454-pyrosequencing. Results: 13 treatment-experienced (8 non-responders, 5 relapsers), and two cirrhotic naïve patients, received telaprevir. +. pegylated-interferon-α. +. ribavirin.Viraemia decay was biphasic. In all patients, first-phase was rapid and consistent, with a median [interquartile-range] viraemia decay of 2.8 [2.6-3.2]. log. IU/ml within 48. h. Second-phase decay was slower, especially in failing patients: 3/3 showed 100. IU/ml at week 2. Only one patient experiencing sustained viral response showed similar kinetics.By pyrosequencing, mutational freeze was observed in all 15 patients within the first 24. h, but only in patients with sustained response afterwards. Indeed, 2/2 failing patients showed early resistance, as minor (V36A-T54A: prevalence

KW - Drug-resistance

KW - Mathematical modelling

KW - Protease inhibitors

KW - Viral kinetic

UR - http://www.scopus.com/inward/record.url?scp=84924068904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924068904&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2014.12.004

DO - 10.1016/j.dld.2014.12.004

M3 - Article

C2 - 25637450

AN - SCOPUS:84924068904

VL - 47

SP - 233

EP - 241

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 3

ER -